It is currently Tue Sep 30, 2014 5:26 pm

News News of Campath (Lemtrada, Alemtuzumab)

Site map of Campath (Lemtrada, Alemtuzumab) » Forum : Campath (Lemtrada, Alemtuzumab)

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

MS drugs Lemtrada and Aubagio launched in Ireland

Genzyme's plans to grow its multiple sclerosis business in Europe continued with the launch of two new treatments in the Republic of Ireland.

The company, which serves as the biotech arm of French pharma firm Sanofi, today launched the injectable Lemtrada (alemtuzumab) in the country just weeks after oral multiple sclerosis (MS) treatment Aubagio (teriflunomide) hit the market...... Read More - http://www.ms-uk.org/lemtrada
Read more : MS drugs Lemtrada and Aubagio launched in Ireland | Views : 206 | Replies : 0


SMC approves Lemtrada for RRMS within NHS Scotland

Scottish Medicines Consortium approves Lemtrada for RRMS within NHS Scotland

"Scotland has one of the highest rates of multiple sclerosis in the world, and the approval of Lemtrada in Scotland is an important step forward for people with active RRMS who remain in need of new treatment options. MS treatments have come a long way in the past twenty years and the availability of Lemtrada provides an opportunity for neurologists to offer a new therapy ...
Read more : SMC approves Lemtrada for RRMS within NHS Scotland | Views : 1565 | Replies : 0


US FDA accepts MS drug Lemtrada resubmission for review

The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
Read more : US FDA accepts MS drug Lemtrada resubmission for review | Views : 1223 | Replies : 0


Alemtuzumab: Do the benefits outweigh the risks?

Alemtuzumab: Do the benefits outweigh the risks in treating multiple sclerosis? http://www.ms-uk.org/lemtrada
Read more : Alemtuzumab: Do the benefits outweigh the risks? | Views : 527 | Replies : 0


NHS patients to get new MS drug

- Scientists have spent 25 years developing treatment at Cambridge
- Alemtuzumab infusion is given in two short courses over two years
- Despite costing £56,000, NICE has ruled treatment is cost-effective......Read More - http://www.ms-uk.org/lemtrada
Read more : NHS patients to get new MS drug | Views : 541 | Replies : 0


Accelerated lymphocyte recovery after alemtuzumab........

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

ABSTRACT

Objective: To test the hypothesis that accelerated peripheral blood mononuclear cell recovery after alemtuzumab treatment of multiple sclerosis is associated with recurrent disease activity and to investigate the claim that CD4 counts greater than 388.5 × 106 cells/mL at 12 months can be used to identify patients who may benefit from further treatment..... Read More - http://www.ms-uk.org/lemtrada
Read more : Accelerated lymphocyte recovery after alemtuzumab........ | Views : 686 | Replies : 0


Lemtrada slows brain atrophy and reduces new MS lesions

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies. <br><br>

- Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension........ Read more - http://www.ms-uk.org/lemtrada
Read more : Lemtrada slows brain atrophy and reduces new MS lesions | Views : 589 | Replies : 0


MS drug Lemtrada to be resubmitted to FDA for approval

Nearly four months after the Food and Drug Administration rejected a multiple sclerosis drug developed by Genzyme, citing the clinical trial’s design and a risk of serious side effects, the Cambridge biotech said Monday that it will resubmit an application for approval to the agency..... Read More - http://www.ms-uk.org/lemtrada
Read more : MS drug Lemtrada to be resubmitted to FDA for approval | Views : 547 | Replies : 0


NICE says 'yes' to Genzyme's MS drug Lemtrada

In final draft guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has recommended the use of French drug major Sanofi subsidiary Genzyme's multiple sclerosis drug Lemtrada (alemtuzumab).

NICE is appraising alemtuzumab as a treatment for adults with relapsing & remitting multiple sclerosis, a chronic and disabling neurological condition that, as it progresses, can have a substantial negative impact on a person&rsquo;s quality of life........ Read More - http://www.ms-uk.org/lemtrada
Read more : NICE says 'yes' to Genzyme's MS drug Lemtrada | Views : 462 | Replies : 0


Lemtrada(R) approved in Mexico for treatment of MS

Genzyme, a Sanofi company, announced today that Mexico's national regulatory authority, COFEPRIS, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing remitting forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations..... Read More - http://www.ms-uk.org/lemtrada
Read more : Lemtrada(R) approved in Mexico for treatment of MS | Views : 646 | Replies : 0


 

Login  •  Register


Statistics

Total posts 220293 • Total topics 22799 • Total members 14388


Contact us | Terms of Service